Physician profile
Barbara Stitt
NPI 1790718476
$1,777.79
in general payments reported to CMS, 2019-2025
14 companies · $816 in 2025
The $816 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.96 · 2022: $160 · 2023: $144 · 2024: $566 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469 · Education: $56.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.31 |
| Education | $56.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $414.84 | 2021-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $355.08 | 2022-2025 | Trelegy Ellipta, Nucala |
| Genentech USA, INC. | $312.98 | 2023-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $237.56 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $111.65 | 2025 | Watchman Flx |
| Amgen INC. | $72.89 | 2024-2025 | Tezspire |
| Genzyme Corporation | $66.99 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $55.14 | 2025 | Neffy |
| Csl Behring | $53.89 | 2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $26.10 | 2025 | |
| Optinose US, INC. | $20.64 | 2021 | |
| Kaleo, INC. | $18.85 | 2022 | |
| Lilly USA, LLC | $18.34 | 2024 | Ebglyss |
| Alk-Abello, INC | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Stitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.